Cinryze is a highly purified, pasteurised and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by FDA in October 2008 for routine prophylaxis against hereditary angioedema(HAE) attacks in adolescent and adult patients.
Daniel Soland, chief operating officer of ViroPharma, said: “Since the launch of Cinryze, patients with HAE who are managed prophylactically with Cinryze, whether they have been trained by their healthcare provider to utilise our self administration option or have their physician administer their doses, have been empowered to take control of their lives.
“We believe that the use of the Mix2Vial in combination with Cinryze offers patients, care givers and physicians a needle-less system to encourage independence and simplify the reconstitution process.”
Fran DeGrazio, vice president of marketing and strategic business development at West, said: “Convenience and simplicity are of the utmost importance for patients and health care providers; our reconstitution system addresses both of these for Cinryze.”